Steve Becker named CCO of Broken String

24 July 2024

UK-based genomics company Broken String Biosciences has appointed Steve Becker as chief commercial officer (CCO).

Broken String’s mission is to advance the next generation of more precise, safe, and effective cell and gene therapies through its technology platforms.  

Mr Becker is a renowned leader in the industry, with more than 30 years’ experience managing diverse teams to develop scalable market development strategies, across start-ups and multi-national organizations. He has successfully launched numerous clinical molecular diagnostics assays and spearheaded strategic growth initiatives for leading life science tools companies. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology